Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial

作者：Zheng Wang, Jia Fan, Shao‐Lai Zhou, Yun‐Fan Sun, Fei Liang, Yuan Ji, Fangming Gu, Tao Li, Li Peng, Tao Peng, Xiaolun Huang, Zhen‐Bin Ding, Dousheng Bai, Bangde Xiang, Guang Tan, Tianfu Wen, Yongyi Zeng, Feng Han, Yu Zhang, Shengdong Wu, Haitao Zhao, Yi Chen, Guo‐Ming Shi, Zhiguo Hou, Ying Sun, Wenqing Zhu, Jian Zhou · 发表于：The Lancet · 年份：2025 · DOI：10.1016/s0140-6736(25)01720-9 · 被引用次数：49 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cancer, Stress, Anesthesia, and Immune Response、Cancer Immunotherapy and Biomarkers